title: Lorazepam-induced modifications of saccadic and smooth-pursuit eye movements in humans: attentional and motor factors.
abstract: In a placebo-controlled, double-blind study, we measured the effects of low dose lorazepam on attentional and motor factors involved in saccadic and smooth pursuit eye movements. We manipulated the temporal interval between the extinction of the central fixation target and the appearance of a second eccentric target (gap/overlap step paradigm). The second target was either stationary (saccade trial) or moving in a direction opposite to the step (pursuit trial). Gap/overlap effects on the latency of saccadic and smooth pursuit eye movements were measured before and after oral intake of either lorazepam or placebo. Pharmacological effects on the dynamics and the accuracy of both types of eye movements were also investigated. In 14 healthy volunteers, we found that the temporal interval between fixation target offset and eccentric target onset modulates the latency of saccadic and smooth pursuit eye movements in a similar way. As compared to placebo, lorazepam significantly increased the latency of both types of eye movements, but did not modify the gap/overlap effect. Moreover, lorazepam significantly decreased the peak velocity of the first saccade towards the eccentric stationary target, as well as the gain of tracking towards the eccentric moving target. However, the overall accuracy of both behaviors was not significantly affected, indicating that systematic errors in foveating or tracking were detected and corrected by appropriate corrective or catch-up saccades, respectively. Results are discussed in terms of shared/different mechanisms for saccadic and pursuit systems in primates.
authors.affiliation: Centre de Recherche en Neurosciences Cognitives, CNRS UPR 9012, Marseille, France. masson@ilnf.cnrs-mrs.fr
authors.forename: G S
authors.initials: GS
authors.lastname: Masson
authors.forename: D R
authors.initials: DR
authors.lastname: Mestre
authors.forename: F
authors.initials: F
authors.lastname: Martineau
authors.forename: C
authors.initials: C
authors.lastname: Soubrouillard
authors.forename: C
authors.initials: C
authors.lastname: Brefel
authors.forename: O
authors.initials: O
authors.lastname: Rascol
authors.forename: O
authors.initials: O
authors.lastname: Blin
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D018757:GABA Modulators / Q000494:pharmacology*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D008140:Lorazepam / Q000494:pharmacology*; D008297:Male; D011698:Pursuit, Smooth / Q000187:drug effects* / Q000502:physiology; D011930:Reaction Time; D012438:Saccades / Q000187:drug effects* / Q000502:physiology
chemical_list: D018757:GABA Modulators; D006993:Hypnotics and Sedatives; D008140:Lorazepam